Isolation and Pharmacological Characterization of α-Elapitoxin-Oh3a, a Long-Chain Post-Synaptic Neurotoxin From King Cobra (Ophiophagus hannah) Venom

Tam M. Huynh¹, Anjana Silva¹,², Geoffrey K. Isbister¹,³ and Wayne C. Hodgson¹*

¹Monash Venom Group, Department of Pharmacology, Biomedical Discovery Institute, Monash University, Clayton, VIC, Australia, ²Department of Parasitology, Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka, Anuradhapura, Sri Lanka, ³Clinical Toxicology Research Group, University of Newcastle, Newcastle, NSW, Australia

The King Cobra (Ophiophagus hannah) is the world’s largest venomous snake and has a widespread geographical distribution throughout Southeast Asia. Despite proteomic studies indicating the presence of postsynaptic neurotoxins in O. hannah venom, there are few pharmacological investigations of these toxins. We isolated and characterized α-elapitoxin-Oh3a (α-EPTX-Oh3a; 7,938 Da), a long-chain postsynaptic neurotoxin, which constitutes 5% of O. hannah venom. α-EPTX-Oh3a (100–300 nM) caused concentration-dependent inhibition of indirect twitches and inhibited contractile responses of tissues to exogenous acetylcholine and carbachol, in the chick biventer cervicis nerve-muscle preparation. The prior incubation of tissues with Thai Red Cross Society King Cobra antivenom (1 ml/0.8 mg) prevented the in vitro neurotoxic effects of α-EPTX-Oh3a (100 nM). The addition of Thai Red Cross Society King Cobra antivenom (1 ml/0.8 mg), at the t90 time point partially reversed the in vitro neurotoxicity of α-EPTX-Oh3a (100 nM). Repeatedly washing the tissue did not allow significant recovery from the in vitro neurotoxic effects of α-EPTX-Oh3a (100 nM). α-EPTX-Oh3a demonstrated pseudo-irreversible antagonism of concentration-response curves to carbachol, with a pA2 of 8.99. De novo sequencing of α-EPTX-Oh3a showed a long-chain postsynaptic neurotoxin with 72 amino acids, sharing 100% sequence identity with Long neurotoxin OH-55. In conclusion, the antivenom is useful for reversing the clinically important long-chain α-neurotoxin-mediated neuromuscular paralysis.

Keywords: Ophiophagus hannah, snake, antivenom, neuromuscular paralysis, neurotoxin

INTRODUCTION

The King Cobra (Ophiophagus hannah) is widely distributed in Southeast Asia, some parts of the Indian subcontinent and Southern China (O’Shea, 2008). Despite typically avoiding human habitat, O. hannah is considered to be a medically important species since, as the world’s largest venomous snake, it is able to inject a large amount of venom in a single bite (Gowtham et al., 2012). Envenoming by O. hannah causes life-threatening neuromuscular paralysis and is usually treated by...
administration of monovalent Thai Red Cross Society King Cobra antivenom (Tin et al., 1991; Tun et al., 1995). Few pharmacological studies have investigated the mechanism of action of O. hannah venom, and isolated neurotoxins, at the skeletal neuromuscular junction. Snake venom neurotoxins are generally classified by their target site at the neuromuscular junction (i.e., post-synaptic or pre-synaptic). Proteomic studies of the venom of O. hannah have indicated a large relative abundance of “postsynaptic” neurotoxins (Petras et al., 2015; Tan et al., 2015), which inhibit neurotransmission by acting as antagonists at the skeletal nicotinic acetylcholine receptor (nAChR) (Barber et al., 2013). Postsynaptic neurotoxins are further classified as short-chain or long-chain neurotoxins, and their structural and functional differences have been previously described in detail (Barber et al., 2013; Utkin, 2019). Recent research has shown that long-chain α-neurotoxins are more clinically important in human envenoming, compared to short-chain α-neurotoxins, due to their higher potency and poor reversibility on the human nAChR (Silva et al., 2018).

Although several α-neurotoxins have been previously isolated from O. hannah venom to study their protein structure (Lin et al., 1995a; Lin et al., 1995b; Chang et al., 1995; Lin et al., 1997; Chang et al., 2000; Roy et al., 2010), there is a need for pharmacological studies to characterize the main neurotoxins that potentially contribute to human neuromuscular paralysis. This study aimed to isolate the main neurotoxins from O. hannah venom and identify the mode of action, as well as determine the in vitro efficacy of Thai Red Cross Society King Cobra antivenom in neutralizing them.

**MATERIALS AND METHODS**

**Venoms and Antivenoms**

Freeze-dried O. hannah venom from Indonesia was a gift from Venom Supplies Tanunda (South Australia). Thai Red Cross Society King Cobra antivenom was purchased from Thai Red Cross Society (Bangkok, Thailand; Batch No: LH00118, expiry date: 13/02/2023). According to the manufacturer’s instructions, 1 ml of the antivenom neutralizes 0.8 mg of O. hannah venom. The amount of antivenom required for neutralizing the in vitro neurotoxicity of the isolated toxin was calculated based on the relative abundance of the toxin in the whole venom.

**Chemicals and Reagents**

The following chemicals and drugs were used: acetylcholine chloride (Sigma-Aldrich, St. Louis, MO, United States), acetic acid sodium salt (sodium acetate, Merck, Darmstadt, Germany), acetonitrile (ACN, Merck, Darmstadt, Germany), ammonium bicarbonate (Sigma-Aldrich, St. Louis, MO, United States), carbamylcholine chloride (carbachol; Sigma-Aldrich, St. Louis, MO, United States), dithiothreitol (Merck, Darmstadt, Germany), formic acid (Sigma-Aldrich, St. Louis, MO, United States), iodoacetamide (GE Healthcare, Uppsala, Sweden), LCMS grade acetonitrile (Fisher Scientific, Loughborough, United Kingdom), potassium chloride (KCl, Ajax Finechem Pty. Ltd., Taren Point, Australia), proteomics grade bovine trypsin (Sigma-Aldrich, St. Louis, MO, United States), trifluoroacetic acid (TFA, Auspep, Melbourne, Australia), d-tubocurarine (Sigma-Aldrich, St. Louis, MO, United States) and trifluoroethanol (Sigma-Aldrich, St. Louis, MO, United States). Unless otherwise indicated, all chemicals were dissolved or diluted in milli-Q water.

**Isolation and Purification of Toxin**

Chromatography was performed using a high-performance liquid chromatography (HPLC) system (Shimadzu, Kyoto, Japan).

**Reverse-Phase HPLC**

Freeze-dried O. hannah venom (2 mg) was reconstituted in 500 μl milli-Q water (Millipore Corporation, Billerca, MA, United States) and centrifuged at 12,000 rpm for 10 min before being loaded into a Phenomenex Jupiter semi-preparative C18 column (5 μm, 250 mm × 10 mm; Phenomenex, Torrance, CA, United States) equilibrated with solvent A (0.1% TFA) at a flow rate of 2 ml/min. The fractions were then eluted using a gradient of solvent B (90% ACN in 0.09% TFA); 0–25% over 10 min, 25%–80% between 10 and 60 min and 80–0% between 60 and 65 min. The eluent was monitored at 214 nm. Fractions were collected manually according to the peaks in the chromatogram and freeze-dried immediately, then later screened using the chick biventer cervicis nerve-muscle preparation to identify those with neurotoxicity.

**Ion-Exchange Chromatography**

Freeze-dried, single run sample of the peak eluting at 19 min from reverse-phase HPLC was reconstituted in 500 μl of buffer A (5 mM sodium acetate; pH 5.1) and loaded into a Mono S strong cation exchange column (8 μm, 8 mm × 75 mm; Showa Denko; Japan). The column was equilibrated with buffer A at a flow rate of 0.5 ml/min. The fractions were eluted using the following gradient of buffer B (5 mM sodium acetate and 0.5 M sodium chloride; pH 5.1): 0% over 10 min, 0–60% between 10 and 70 min and 60–0% between 70 and 75 min. The eluent was monitored at 280 nm. Toxin 1C was collected manually at 52 min and then subsequently freeze-dried to be ready for further analysis.

**Mass Spectrometry and Amino Acid Sequencing**

Intact Protein Analysis With Matrix Associated Laser Desorption Time of Flight (MALDI-TOF) Mass Spectrometry

Venom fractions were analysed by LC-MS using a quadrupole TOF mass spectrometer (MicroTOFQ, Bruker Daltonics, Bremen, Germany) coupled online with a 1,200 series capillary HPLC (Agilent Technologies, Santa Clara, CA, United States). Samples were injected onto a MabPac SEC-1 5μm, 300A, 50 × 4 mm (Thermo Scientific) column with 50% acetonitrile 0.05% TFA, 0.05% FA at a flow rate of 50 μl/min. The protein was eluted over a 20 min run-time monitored by UV detection at 254 nm. The eluant was nebulised and ionised using the Bruker electrospray...
source with a capillary voltage of 4500 V dry gas at 180°C, a flow rate of 4 l/min and nebuliser gas pressure at 300 mbar. After 20 min, the flow path was switched to infuse Low concentration Tune mix (Agilent Technologies, Santa Clara, CA, United States) to calibrate the spectrum post-acquisition. The spectra were extracted and deconvoluted using Data explorer software version 3.4 build 192 (Bruker Daltonics, Bremen, Germany).

Electrospray-Ionisation Coupled With Mass-Spectrometry/Mass Spectrometry (ESI-LCMS/MS)
The sample (2.5–5 µg) was buffer exchanged into 50 mM ammonium bicarbonate and reduced in 2.5 mM DTT at 60°C for 5 min followed by alkylation with 10 mM chloroacetamide for 30 min at room temperature. The enzyme was then added at the rate of 0.5 µg per 10 µg of protein and incubated at 37°C overnight. For chymotrypsin digest 50 mM Tris buffer was used in place of ammonium bicarbonate.

All enzyme digests were analysed by LC-MS/MS using the QExactive mass spectrometer (Thermo Scientific, Bremen, Germany) coupled online with a RSLC nano HPLC (Ultimate 3000, Thermo Scientific, Bremen, Germany). Sample (200 ng) was injected and concentrated on a 100 µm, 2 cm nanoviper pepmap100 trap column with 97.5% buffer A (0.1% TFA) at a flow rate of 15 µl/min. The peptides then eluted and separated with a Thermo RSLC pepmap100, 75 µm × 50 cm, 100 Å pore size, reversed phase nano column with a 30 min gradient of 92.5% buffer A (0.1% formic acid) to 42.5% B (80% ACN 0.1% formic acid), at a flow rate of 250 nl/min. The peptides were ionised using the Thermo nano electrospray source with a distal capillary voltage of 1900 V. Peptides were selected for MSMS analysis in Full MS/dd-MS2 (TopN) and were re-added as above. Twitch responses and responses to exogenous agonists were measured via a Grass FT03 force displacement transducer and recorded on a PowerLab system (ADInstruments Pty Ltd., Australia).

De Novo Protein Sequencing
Data from the LCMS/MS acquisitions was analysed using Peaks AB Ver. 2.0 (Bioinformatics Solutions Inc., Ont, Canada), to derive a de novo protein sequence. The following search parameters were used: missed cleavages, 2; peptide mass tolerance, ± 10 ppm; peptide fragment tolerance, ± 0.05 Da; fixed modifications, carbamidomethyl (Cys); Variable modification, oxidation (Met).

Sequences were validated using Byonic (ProteinMetrics) V 3.1–19 and a precursor and fragment mass tolerance of 20 ppm. Modifications specified were Carbamidomethyl @C fixed and Oxidation @M Variable common 1. The protein output was set to 1% FDR.

Chick Biventer Cervicis Nerve-Muscle Preparation
Male chickens (aged 4–10 days) were killed by exsanguination following CO2 inhalation. Biventer cervicis nerve-muscle preparations were dissected and then mounted on wire tissue holders under 1 g resting tension in 5 ml organ baths. Tissues were maintained at 34°C, bubbled with 95% O2 and 5% CO2, in physiological salt solution of the following composition (mM): 118.4 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4, 2.5 CaCl2, 25 NaHCO3 and 11.1 glucose. Indirect twitches were evoked by stimulating the motor nerve (0.1 Hz; 0.2 ms) at supramaximal voltage (10–20 V), using a Grass S88 stimulator (Grass Instruments, Quincy, MA). Selective stimulation of the nerve was confirmed by the abolishment of twitches by the addition of d-tubocurarine (10 µM). Tissues were then repeatedly washed with physiological salt solution to restore twitch response to nerve stimulation. Contractile responses of the tissues to exogenous acetylcholine (ACh; 1 mM for 30 s), carbachol (CCh; 20 µM for 60 s) and KCl (40 mM for 30 s) were obtained in the absence of nerve stimulation. Nerve stimulation was then recommenced for at least 30 min before the addition of the toxin or antivenom.

To examine the ability of antivenom to neutralise α-elapitoxin-Oh3a (i.e., prevention study), tissues were equilibrated with antivenom for 10 min before the toxin was added. To determine the ability of antivenom to reverse α-elapitoxin-Oh3a induced neurotoxicity (i.e., reversal study), antivenom was added at t90 (i.e., time at which the initial twitch height was inhibited by 90%). To examine the reversible nature of the binding of α-elapitoxin-Oh3a to skeletal nAChR, organ baths were repeatedly washed for a period of 10 s every 5 min until any recovery of twitch responses had plateaued.

At the conclusion of each experiment, ACh, CCh and KCl were re-added as above. Twitch responses and responses to exogenous agonists were measured via a Grass FT03 force displacement transducer and recorded on a PowerLab system (ADInstruments Pty Ltd., Australia).

Cumulative Concentration-Response Curves to Carbachol
In order to determine the potency (i.e., pA2 value) of α-elapitoxin-Oh3a, cumulative concentration–response curves to CCh (0.6–80 µM) were obtained by adding increasing concentrations of the agonist to unstimulated chick preparations without washing the preparation between each addition. After the maximum response was achieved, the tissue was repeatedly washed and allowed to recover for 30 min. Then α-elapitoxin-Oh3a (1–30 nM) or vehicle (milli-Q water) was allowed to equilibrate with the tissue for 60 min before the cumulative concentration–response curve to CCh was repeated in the presence of toxin or vehicle.

Data Analysis
The quantity of α-elapitoxin-Oh3a in the whole venom was determined by measuring the area under the curve of the reverse-phase HPLC and ion-exchange chromatograms with the single peak representing α-elapitoxin-Oh3a being expressed as a percentage of the total area under the curve of whole venom.

Nerve-mediated twitch responses and responses to ACh (30 s), CCh (60 s) and KCl (30 s) were measured via a Grass FT03 force...
displacement transducer and recorded on PowerLab system (ADInstruments Pty Ltd., Australia). Post-venom/toxin responses were expressed as a percentage of their initial responses. An unpaired t-test or one-way analysis of variance (ANOVA) was used to compare the effect on twitch height of different pre-treatments. Comparison of responses to exogenous agonists before and after pre-treatment was made using a Student’s paired t-test. In order to determine the antagonist potency (i.e., pA2) of α-elapitoxin-Oh3a, the shifts in the cumulative concentration-response curves to CCh, in the absence or presence of α-elapitoxin-Oh3a, were analysed using the modified Lew Angus method. All ANOVAs were followed by a Bonferroni’s multiple comparison post-hoc test. Data presented are in the form of mean ± standard error of the mean (SEM) of n experiments. All data and statistical analyses were performed using PRISM 9.2.0 (GraphPad Software, San Diego, CA, United States, 2016). For all statistical tests, p < 0.05 was considered statistically significant.

RESULTS

In Vitro Neurotoxicity of the Whole Venom
O. hannah venom (1–10 µg/ml) caused concentration-dependent inhibition of indirect twitches in the chick biventer cervicis nerve-muscle preparation (n = 4; p < 0.05, one-way ANOVA; Figure 1A). All concentrations of the venom also abolished contractile responses of tissues to exogenous ACh and CCh (n = 4; p < 0.05, paired t-test; Figure 1B), but not KCl. The reduction of responses to ACh and CCh, without affecting the responses to KCl, indicates a postsynaptic mode of action.

Fractionation of Venom via Reverse-phase HPLC and Ion-Exchange Chromatography
α-Elapitoxin-Oh3a was isolated from O. hannah venom using reverse-phase HPLC followed by ion-exchange chromatography. Fractionation of whole venom by reverse-phase HPLC on a Jupiter C18 semi-preparative column yielded several major and minor peaks (Figure 2A). Initial screening of all fractions from reverse-phase HPLC, in the chick biventer nerve-muscle preparation, showed that peak 1, peak 2, peak 3 and peak 4, which eluted at 19, 20, 22 and 23 min, respectively, displayed postsynaptic neurotoxicity. Peak 1 was further purified using ion-exchange chromatography on a Mono S strong cation exchange column, producing several additional fractions (Figure 2B). Initial screening of these fractions, in the chick biventer nerve-muscle preparation, showed that peak 1C, which eluted at 52 min, displayed postsynaptic neurotoxicity. Fraction 1C, subsequently named α-elapitoxin-Oh3a, was subjected to further purification using ion-exchange chromatography, resulting in a clean peak (Figure 2C). α-Elapitoxin-Oh3a is estimated to constitute approximately 5% of the whole venom protein content. The neurotoxins within peak 2, peak 3 and peak 4 could not be further purified using the current chromatographic methods.

Intact Protein Analysis With MALDI-TOF Mass Spectrometry
Intact protein analysis of α-elapitoxin-Oh3a using MALDI-TOF showed a single mass with a molecular weight of 7,938.4 Da (Figure 3).

De Novo Protein Sequencing and Protein Identification
Enzyme digest using ESI-LCMS/MS generated the following full amino acid sequence of α-elapitoxin-Oh3a (72 amino acids) which was validated using Byonic (ProteinMetrics) V 3.1–19.

TKGYVPDPVKSETPCPGQGQCY TETWCDAWCTSRTGKRVNLGCAATCPVKGVEI EKCSDDNCPFPTRKR

α-Elapitoxin-Oh3a showed 100% sequence identity with Long neurotoxin OH-55 (UniProtKB-Q53B58) and was assigned the name “α-elapitoxin-Oh3a” based on the rational nomenclature.
**FIGURE 2** Chromatograms of *O. hannah* venom showing the fractionation steps to purify α-Elapitoxin-Oh3a. (A) *O. hannah* venom by reverse-phase HPLC on a Jupiter C18 semi-preparative column; (B) fractionation of peak 1 by ion-exchange chromatography on a Mono S strong cation exchange column; (C) further purification of peak 1C by ion-exchange chromatography on a Mono S strong cation exchange column.
for naming peptide toxins from spiders and other venomous animals suggested by King et al. (2008). α-Elapitoxin-Oh3a showed more than 80% sequence homology with the long-chain α-neurotoxins, long neurotoxin 1, long neurotoxin 2, long neurotoxin 3, long neurotoxin OH-34, long neurotoxin OH-56 isolated from the venom of O. hannah (Figure 4).
In Vitro Neurotoxicity of α-Elapitoxin-Oh3a

Concentration-Dependent Inhibition of Twitches and Exogenous Agonists Responses

α-Elapitoxin-Oh3a (100–300 nM) caused concentration-dependent inhibition of indirect twitches in the chick biventer cervicis nerve-muscle preparation (n = 4; p < 0.05, one-way ANOVA; Figure 5A). Both concentrations of the toxin inhibited responses of tissues to exogenous ACh and CCh (n = 4; p < 0.05, paired t-test; Figure 5B), but not KCl. The reduction of responses to ACh and CCh, without affecting the responses to KCl, indicates a postsynaptic mode of action.

In Vitro Neurotoxicity Antivenom Prevention Study

The prior incubation of tissues with Thai Red Cross Society King Cobra antivenom (1 ml/0.8 mg) prevented the inhibition of indirect twitches by α-elapitoxin-Oh3a (100 nM; n = 4; p < 0.05, unpaired t-test; Figure 6A) and prevented the reduction of contractile responses to ACh and CCh (n = 4; p < 0.05, paired t-test; Figure 6B).

In Vitro Neurotoxicity Antivenom Reversal and Washing Study

The addition of Thai Red Cross Society King Cobra antivenom (1 ml/0.8 mg), at the t90 time point following the effect of α-elapitoxin-Oh3a (100 nM), partially restored the twitch responses to 42.0 ± 14.3% (n = 4; p < 0.05, one-way ANOVA; Figure 7A) of the pre-toxin twitch height by the 180 min time point. The toxin-induced reduction of responses to ACh and CCh was also significantly prevented by the delayed addition of antivenom (n = 4; p < 0.05, paired t-test; Figure 7B).

Repeatedly washing the tissue for 10 s every 5 min, commencing at the t90 time point following addition of α-elapitoxin-Oh3a (100 nM), only caused a slight recovery of the twitch responses to 6.4 ± 5.6% (n = 4; Figure 7A). Repeated
washed also partially reversed the inhibition of responses to ACh and CCh (n = 4; p < 0.05, paired t-test; Figure 7B).

**Carbachol Cumulative Concentration-Response Curves**

α-Elapitoxin-Oh3a (1–30 nM) caused a concentration-dependent non-parallel shift of the cumulative concentration-response curve to CCh, with a concentration-dependent reduction of the maximum response in unstimulated chick biventer cervicis nerve-muscle preparations (Figure 8). This indicates that α-elapitoxin-Oh3a is pseudo-irreversible antagonist at skeletal nAChR. Using the modified Lew and Angus method, the pA2 value of α-elapitoxin-Oh3a was calculated to be 8.99 (95% c.l.: 8.00–9.90).

**DISCUSSION**

In this study, we examined the *in vitro* neurotoxicity of *O. hannah* venom, and isolated and characterized a long-chain postsynaptic α-neurotoxin, α-elapitoxin-Oh3a. The *in vitro* neurotoxicity of α-elapitoxin-Oh3a was neutralized, and partially reversed, by Thai Red Cross Society King Cobra antivenom. Administration of antivenom provided more recovery than repeated washing of the tissue. α-Elapitoxin-Oh3a also demonstrated irreversible or “pseudo-irreversible” antagonism at avian skeletal nAChR.

*O. hannah* venom demonstrated postsynaptic neurotoxicity in the indirectly stimulated chick biventer nerve-muscle preparation as indicated by the concentration-dependent inhibition of indirect twitches and reduction in contractile responses to external nicotinic agonists. This observation is consistent with proteomic reports suggesting a large abundance of postsynaptic neurotoxins in the venom (Petras et al., 2015; Tan et al., 2015).

α-Elapitoxin-Oh3a was isolated using reverse-phase HPLC and ion-exchange chromatography, and shown to constitute approximately 5% of *O. hannah* venom. With a molecular mass of 7,938.4 Da, and consisting of 72 amino acids, α-elapitoxin-Oh3a exhibits traits consistent with those of long-chain postsynaptic neurotoxins (Barber et al., 2013). Further, α-elapitoxin-Oh3a was calculated to have a pA2 value of 8.99, indicating a high potency in terms of its antagonist activity at the nAChR. For comparison, the pA2 of α-bungarotoxin, a potent long-chain α-neurotoxin, determined using the same methodology as the current study, was calculated to be 8.71 (Wickramaratna et al., 2004). Our experiments also suggest that the antagonism of α-elapitoxin-Oh3a is irreversible or pseudo-irreversible. All the above are suggestive of α-elapitoxin-Oh3a being a typical long-chain α-neurotoxin (Barber et al., 2013).

Additionally, we identified three fractions from reverse-phase HPLC which displayed postsynaptic neurotoxicity, but the α-neurotoxins within these fractions could not be further purified using ion-exchange chromatography. The presence of multiple α-neurotoxins in *O. hannah* venom from Indonesia, has also been previously indicated by proteomic analysis (Petras et al., 2015), with approximately 37% of the venom protein identified as postsynaptic neurotoxins. α-Elapitoxin-Oh3a showed 100% sequence identity with Long neurotoxin OH-55, which was also reported by the aforementioned study to constitute approximately 12% of the venom, slightly more than the relative abundance suggested in the current study.

Long neurotoxin OH-55 has also been isolated from *O. hannah* venom by He et al. (2004). In this previous study, a 24 h LD50 assay of the isolated α-neurotoxins from *O. hannah* venom in mice showed Long neurotoxin OH-55 to have a LD50 of 120 ng/g (i.p.), likely due to a high potency on the mouse (rodent) nAChR. Unlike short-chain α-neurotoxins, long-chain α-neurotoxins do not show a difference in the potency and reversibility between human and rodent nAChR. Therefore, they are likely to be more clinically important and capable of causing neuromuscular paralysis in humans (Silva et al., 2018). Hence, it could be assumed that α-elapitoxin-Oh3a, which constitutes 5–12% of the whole venom, would be of high clinical importance in causing neuromuscular paralysis in envenomed humans.

Thai Red Cross Society King Cobra antivenom was able to fully prevent the neurotoxic effects of α-elapitoxin-Oh3a, indicating the presence of antibody fragments against the toxin. Further, the antivenom was able to partially restore (~40%) the indirect twitches of the chick biventer preparation after they were fully inhibited by the toxin. The continuous physical removal of α-elapitoxin-Oh3a, by repeated washing of the preparation, did not result in any significant reversal of the neurotoxic effect of the toxin on indirect twitches although there was partial restoration of the responses to exogenous agonists. Since the constant removal of toxin from the surrounding physiological environment is unable to effectively reverse the neuromuscular block, this suggests that the role of antivenom may not be limited to antibodies binding to epitopes at the pharmacological site of unbound toxins, preventing their antagonism at nAChRs, but antibodies may also bind to epitopes more distant from the pharmacological site of nAChR-bound toxins, triggering conformational changes in the toxin that would reduce its affinity for nAChRs (Silva and Isbister, 2020). This was previously demonstrated by commercially used antivenoms and high-affinity monoclonal antibodies which could accelerate the detachment of *Naja nigricollis* toxin α from nAChRs (Boulain and Ménez, 1982; Boulain et al., 1985; Gatineau et al., 1988). In contrast to α-elapitoxin-Oh3a, toxin α is a short-chain postsynaptic neurotoxin, which generally have a lower potency and higher reversibility at nAChRs, and likely to be of lesser clinical importance (Silva et al., 2018). The important observation made in this study is that antivenom can reverse the clinically important long-chain α-neurotoxin-mediated neuromuscular paralysis.

In conclusion, we have shown that α-Elapitoxin-Oh3a (7,938 Da), a long-chain α-neurotoxin from *O. hannah* venom, is a highly potent pseudo-irreversible antagonist at nAChR in avian skeletal muscle. The neurotoxic effects of α-Elapitoxin-Oh3a are prevented, and partially reversed, by Thai Red Cross Society King Cobra antivenom. α-Elapitoxin-Oh3a is likely to be a key contributor the neuromuscular paralysis that can result by envenoming by the King Cobra.

**DATA AVAILABILITY STATEMENT**

The protein sequence data reported in this paper is available in the UniProt Knowledgebase under the accession number Q53B58.
ETHICS STATEMENT

The animal study was reviewed and approved by Monash University Ethics Committee on 18 December 2019; ethics number 22575.

AUTHOR CONTRIBUTIONS

TH: experiments, data acquisition, data analysis, writing. AS: experiment design, data analysis, writing, funding acquisition. GI: experiment design, data acquisition, data analysis, writing. WH: experiment design, writing, funding acquisition.

REFERENCES

Barber, C. M., Ibister, G. K., and Hodgson, W. C. (2013). Alpha Neurotoxins. Toxicon 66, 47–58. doi:10.1016/j.toxicon.2013.01.019

Boulain, J. C., and Ménez, A. (1982). Neurotoxic-Specific Immunoglobulins Accelerate Dissociation of the Neurotoxin-Acetylcholine Receptor Complex. Science 217, 732–733. doi:10.1126/science.7109919

Boulain, J. C., Fromageot, P., and Ménez, A. (1985). Further Evidence Showing that Neurotoxin-Acetylcholine Receptor Dissociation Is Accelerated by Monoclonal Neurotoxin-specific Immunoglobulin. Mol. Immunol. 22, 553–556. doi:10.1016/0161-5809(85)90178-6

Chang, C.-C., Lin, P.-M., Chang, L.-S., and Kuo, K.-W. (1995). Chemical Modification of Tryptophan Residues in α-neurotoxins from Ophiophagus hannah (King Cobra) Venom. J. Protein Chem. 14, 89–94. doi:10.1007/BF0188366

Chang, L., Chang, C., and Lin, S. (2000). Differential Contribution of the Conserved Tyrosine Residues to Activity and Structural Stability of Ophiophagus hannah α-Neurotoxins. J. Pept. Res. 55, 240–245. doi:10.1034/j.1399-3011.2000.00176.x

Gatineau, E., Lee, C. Y., Fromageot, P., and Menez, A. (1988). Reversal of Snake Neurotoxin Binding to Mammalian Acetylcholine Receptor by Specific Antiserum. Eur. J. Biochem. 171, 535–539. doi:10.1111/j.1432-1033.1988.tb13822.x

Gowtham, Y. J., Kumar, M. S., Girish, K. S., and Kemparaju, K. (2012). Hemostatic Interference of Indian King Cobra (Ophiophagus hannah) Venom. Comparison with Three Other Snake Venoms of the Subcontinent. Biochemistry (Mosc) 77, 639–647. doi:10.1134/S0006297912060119

He, Y. Y., Lee, W. H., and Zhang, Y. (2004). Cloning and Purification of α-Neurotoxins from king Cobra (Ophiophagus hannah). Toxicon 44, 295–303. doi:10.1016/j.toxicon.2004.06.003

King, G. F., Gentz, M. C., Escoubas, P., and Nicholson, G. M. (2008). A Rational Nomenclature for Naming Peptide Toxins from Spiders and Other Venomous Animals. Toxicon 52, 264–276. doi:10.1016/j.toxicon.2008.05.020

Lin, S. R., Chi, S. H., Chang, L. S., Kuo, K. W., and Chang, C. C. (1995a). Chemical Modification of Cationic Groups of a Novel α-Neurotoxin (Oh-4) from King Cobra (Ophiophagus hannah) Venom. J. Biochem. 118, 297–301. doi:10.1093/oxfordjournals.jbchem.a124906

Lin, S. R., Chi, S. H., Chang, L. S., Kuo, K. W., and Chang, C. C. (1995b). Chemical Modification of Cationic Residues in Toxin α from King Cobra (Ophiophagus hannah) Venom. J. Protein Chem. 15, 95–101. doi:10.1007/bf01866810.1007/bf01866815

Lin, S. R., Lee, L. F., Chang, L. S., and Chang, C. C. (1997). Acidic Amino Sequence and Chemical Modification of a Novel α-Neurotoxin (Oh-5) from King Cobra (Ophiophagus hannah) Venom. J. Biochem. 121, 690–695. doi:10.1093/oxfordjournals.jbchem.a021641

O’Shea, M. (2008). Venomous Snakes of the World, London, UK: New Holland Publishers.

Petras, D., Heiss, P., Süssmuth, R. D., and Calvete, J. J. (2015). Venom Proteomics of Indonesian King Cobra, Ophiophagus hannah: Integrating Top-Down and Bottom-Up Approaches. J. Proteome Res. 14, 2539–2556. doi:10.1021/acs.jproteome.5b00305

FUNDING

This study was supported by an Australian National Health and Medical Research Council (NHMRC) Senior Research Fellowship (ID: 1154503) awarded to GI, and a NHMRC Centres for Research for Excellence Grant (ID: 1110343) awarded to GI and WH.

ACKNOWLEDGMENTS

We would also like to acknowledge the Monash Proteomics & Metabolomics Facility and Dr David Steer for determining the intact mass and amino acid sequence of the toxin.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Huynh, Silva, Ibister and Hodgson. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.